FDA raises more concerns about Ranbaxy’s India plants, shares fall

The Food and Drug Administration (FDA) has raised concerns about the manufacturing practices at a factory owned by Ranbaxy Laboratories Ltd, the Indian drugmaker said on Monday, sending its shares down to nearly a one-month low. All of Ranbaxy's India-based factories are currently banned by the FDA from exporting medicines to the United States, the company's largest market, after the regulator's inspection found violation of its so-called good manufacturing practices. The company, India's biggest drugmaker by sales, said the FDA had now filed "certain observations" about its Toansa pharmaceutical ingredients plant in the northern state of Punjab. Failure to address these concerns would result in the FDA banning all exports to the United States from the factory.